Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Serum CA-125, a glycoprotein antigen, has been measured in serum of patients with ovarian cancer, cervical cancer, or nonseminomatous germ-cell tumor of testis. Increased concentrations were found in 21 of 27 patients with epithelial ovarian cancer and two of three patients with ovarian teratoma. Changes in CA-125 concentrations in serum during chemotherapy mirrored the progress of the disease as assessed by clinical and radiological evidence. Although CA-125 provides no real asset for diagnosis, it should have value as a marker for monitoring response to chemotherapy.


Journal article


Clin Chem

Publication Date





1124 - 1125


Adult, Antigens, Neoplasm, Antigens, Surface, Antigens, Tumor-Associated, Carbohydrate, Carboplatin, Carcinoma, Female, Humans, Male, Neoplasms, Germ Cell and Embryonal, Organoplatinum Compounds, Ovarian Neoplasms, Teratoma, Testicular Neoplasms, Uterine Cervical Neoplasms